ReviewFrontiers in pharmacology2021
New Developments in Prokinetic Therapy for Gastric Motility Disorders.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Efficacy of antidepressants in functional dyspepsia: Systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Pooled it
- The role of diet in diabetes gastroparesis treatment: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Mosapride versus Metoclopramide in Critically Ill Patients with Enteral Feeding Intolerance: A Randomized, Double-Blinded Comparison.Drug design, development and therapy · 2026Trial
- Intravenous metoclopramide for increasing endoscopic mucosal visualization in patients with acute upper gastrointestinal bleeding: a multicenter, randomized, double-blind, controlled trial.Scientific reports · 2024Trial
- Serotonergic System Dysregulation in Alzheimer's Disease.ACS chemical neuroscience · 2026Review
- Gastroparesis in Parkinson's disease: Diagnostic and clinical implications for optimizing pharmacological treatment.Journal of Parkinson's disease · 2026Review
- Malnutrition and Sarcopenia in Gastrointestinal Motility Disorders: Mechanisms, Assessment, and Management.Current gastroenterology reports · 2026Review
- Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Mechanisms of Xinwei Tang in stress-induced gastric dysmotility: evidence from rat and In Vitro models.In vitro cellular & developmental biology. Animal · 2026Article
- Gastrointestinal Complaints After Fundoplication: Rapid Review and Evidence Mapping.Current gastroenterology reports · 2026Review
- Progress in Gastroparesis Management: From Pharmacotherapy to Interventional Treatments.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Chlorpromazine versus Metoclopramide for Neurogenic Nausea and Vomiting in Incurable Patients with Gastrointestinal Tumors: A Prospective Observational Cohort Study.Cancer management and research · 2026Article
- Recent Developments in Oral Drug Delivery of Prokinetic Agents: Nanoparticles and Beyond.Current drug delivery · 2026Review
- Magnetic Resonance Imaging of Gastric Motility in Conscious Rats.Neurogastroenterology and motility · 2026Article
- Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Gastroparesis, a diabetic complication causing further, even serious, complications: How to prevent its worsening?World journal of gastroenterology · 2025Article
- Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients Under Enteral Feeding; A Comparative Controlled Randomized Trial.Anesthesiology and pain medicine · 2025Article
- Pathophysiological mechanisms of functional dyspepsia: a narrative review.Frontiers in medicine · 2025Article
- Metoclopramide combined with probiotics improves gastric retention in mechanically ventilated patients following craniocerebral surgery.Frontiers in nutrition · 2025Article
- A rare case of antidepressant discontinuation syndrome triggered by domperidone: Clinical insights and literature review.SAGE open medical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA's program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.